{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:12:42Z","timestamp":1776269562610,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.vaccine.2015.06.046","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T05:47:33Z","timestamp":1434520053000},"page":"3628-3635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines"],"prefix":"10.1016","volume":"33","author":[{"given":"Ernesto","family":"Oviedo-Orta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohail","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2015.06.046_bib0280","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinids\/3.2.246","article-title":"The epidemiology of pneumococcal disease in infants and children","volume":"3","author":"Klein","year":"1981","journal-title":"Rev Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.046_bib0285","first-page":"297","article-title":"Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine","volume":"8","author":"Takala","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0290","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.med.51.1.407","article-title":"Global epidemiology of influenza: past and present","volume":"51","author":"Cox","year":"2000","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0295","unstructured":"Glossary. 2014. http:\/\/www.cdc.gov\/excite\/library\/glossary.htm-outbreakpointsource."},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.046_bib0300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/504804","article-title":"Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994\u20132002","volume":"43","author":"Brooks","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.vaccine.2015.06.046_bib0305","first-page":"1","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metrics"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0310","unstructured":"http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2014-10.html."},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.06.046_bib0315","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2334-6-25","article-title":"Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan","volume":"6","author":"Chiou","year":"2006","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0325","first-page":"341","article-title":"Epidemiology of meningococcal disease in North America","volume":"67","author":"Pollard","year":"2001","journal-title":"Methods Mol Med"},{"issue":"9911","key":"10.1016\/j.vaccine.2015.06.046_bib0330","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0335","series-title":"Meningococcal vaccines","author":"Granoff","year":"2004"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.046_bib0340","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1086\/315158","article-title":"The changing epidemiology of meningococcal disease in the United States, 1992\u20131996","volume":"180","author":"Rosenstein","year":"1999","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.046_bib0345","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/520303","article-title":"Complications and sequelae of meningococcal disease in Quebec Canada, 1990\u20131994","volume":"26","author":"Erickson","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.046_bib0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.06.046_bib0355","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of meningococcal group B vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0360","series-title":"HealthMap","author":"Hospital BCs","year":"2006"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0365","series-title":"Infectious disease informatics: syndromic surveillance for public health and biodefense","author":"Daniel","year":"2010"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.046_bib0370","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.meegid.2008.04.002","article-title":"Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease","volume":"8","author":"Caugant","year":"2008","journal-title":"Infect Genet Evol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.046_bib0375","first-page":"1458","article-title":"Meningococcal disease in Sao Paulo Brazil, in the 20th century: epidemiological characteristics","volume":"21","author":"de Moraes","year":"2005","journal-title":"Cad Saude Publica"},{"issue":"14","key":"10.1016\/j.vaccine.2015.06.046_bib0380","first-page":"1466","article-title":"Meningococcic meningitis in Troms and Finnmark","volume":"90","author":"Hoyer","year":"1970","journal-title":"Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke"},{"issue":"4","key":"10.1016\/j.vaccine.2015.06.046_bib0385","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/135.4.669","article-title":"Neisseria meningitidis infections in Northern Norway: an epidemic in 1974\u20131975 due mainly to group B organisms","volume":"135","author":"Bovre","year":"1977","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.046_bib0390","first-page":"75","article-title":"Some agent characteristics and their coexistence related to occurrence and severity of systemic meningococcal disease in Norway, Winter 1981\u20131982","volume":"6","author":"Bovre","year":"1983","journal-title":"NIPH Ann"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.046_bib0395","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1017\/S0950268806006248","article-title":"High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985\u20132002","volume":"134","author":"Smith","year":"2006","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.046_bib0400","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1017\/S0950268805004553","article-title":"Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985\u20132002","volume":"134","author":"Smith","year":"2006","journal-title":"Epidemiol Infect"},{"issue":"8775","key":"10.1016\/j.vaccine.2015.06.046_bib0405","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.vaccine.2015.06.046_bib0410","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2007.01.022","article-title":"Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease","volume":"25","author":"Nokleby","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.046_bib0415","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37757\/MR2007V9.N1.6","article-title":"Cuban meningococcal BC vaccine: experiences & contributions from 20 years of application","volume":"9","author":"Sotolongo","year":"2007","journal-title":"MEDICC Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.046_bib0420","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/CVI.00230-06","article-title":"Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents","volume":"14","author":"Boutriau","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.046_bib0425","first-page":"34","article-title":"Meningococcal disease and VA-MENGOC BC in minors less than 1 year of age. Cuba, 1983 to 1991","volume":"48","author":"Rico Cordeiro","year":"1996","journal-title":"Rev Cubana Med Trop"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.046_bib0430","first-page":"59","article-title":"The post-licensing efficacy of VA-MENGOC-BC in children under 6 in Holguin, Cuba. The first year of observation","volume":"47","author":"Rico Cordeiro","year":"1995","journal-title":"Rev Cubana Med Trop"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.046_bib0435","first-page":"94","article-title":"Effectiveness of VA-MENGOC-BC in children from 0 to 5 years of age in Cuba First year of observation","volume":"46","author":"Rico Cordeiro","year":"1994","journal-title":"Rev Cubana Med Trop"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.046_bib0440","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4161\/hv.18500","article-title":"Bexsero: a multicomponent vaccine for prevention of meningococcal disease","volume":"8","author":"Gorringe","year":"2012","journal-title":"Hum Vaccines Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.046_bib0445","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1084\/jem.138.5.1156","article-title":"Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis","volume":"138","author":"Devoe","year":"1973","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0450","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.046_bib0455","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","article-title":"New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4","volume":"177","author":"Martin","year":"1998","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.046_bib0460","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1017\/S0950268805004954","article-title":"Clonal analysis of the serogroup B meningococci causing New Zealand's epidemic","volume":"134","author":"Dyet","year":"2006","journal-title":"Epidemiol Infect"},{"issue":"16","key":"10.1016\/j.vaccine.2015.06.046_bib0465","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.046_bib0470","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2015.06.046_bib0475","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/adc.2007.132571","article-title":"Phase II meningococcal B vesicle vaccine trial in New Zealand infants","volume":"94","author":"Jackson","year":"2009","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.046_bib0480","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/INF.0b013e318195205e","article-title":"Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine","volume":"28","author":"Wong","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0485","series-title":"The epidemiology of meningococcal disease in New Zealand 2011","author":"Lopez","year":"2011"},{"issue":"17\/18","key":"10.1016\/j.vaccine.2015.06.046_bib0490","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","article-title":"The concept of \u201ctailor-made\u201d, protein-based, outer membrane vesicle vaccines against meningococcal disease","volume":"23","author":"Holst","year":"2005","journal-title":"Vaccine"},{"issue":"1010","key":"10.1016\/j.vaccine.2015.06.046_bib0495","first-page":"437","article-title":"Meningococcal disease epidemiology and control in New Zealand","volume":"108","author":"Wilson","year":"1995","journal-title":"N Z Med J"},{"issue":"1085","key":"10.1016\/j.vaccine.2015.06.046_bib0500","first-page":"115","article-title":"Meningococcal disease in Auckland July 1992\u2013June 1994","volume":"112","author":"Jefferies","year":"1999","journal-title":"N Z Med J"},{"issue":"40","key":"10.1016\/j.vaccine.2015.06.046_bib0505","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.046_bib0510","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"40","key":"10.1016\/j.vaccine.2015.06.046_bib0515","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1016\/j.vaccine.2013.06.080","article-title":"Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage","volume":"31","author":"Delbos","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0520","series-title":"Selected reportable communicable disease summary: 2008\u20132009. Meningococcal disease","author":"Data ODS","year":"2009"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0525","unstructured":"https:\/\/public.health.oregon.gov\/DiseasesConditions\/DiseasesAZ\/MeningococcalDisease\/Pages\/Meningococcal-Update.aspx."},{"key":"10.1016\/j.vaccine.2015.06.046_bib0530","series-title":"Princeton University meningococcal disease outbreak","author":"Prevention CfDCa","year":"2014"},{"key":"10.1016\/j.vaccine.2015.06.046_bib0535","series-title":"Meningococcal disease","author":"Atkinson","year":"2012"},{"issue":"11","key":"10.1016\/j.vaccine.2015.06.046_bib0540","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/00006454-199611000-00012","article-title":"Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease","volume":"15","author":"Jackson","year":"1996","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.046_bib0545","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cid\/cit243","article-title":"Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States","volume":"57","author":"Mandal","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.046_bib0550","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500835X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500835X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T14:16:29Z","timestamp":1691763389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1500835X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":55,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0264410X1500835X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}